Home / Intelligence / Case Studies / Mapping Payer & Employer Perceptions of Novel Migraine Therapies to Support Access Strategy Development
Trinity conducted a payer and employer advisory board to understand current perceptions of novel migraine therapies and potential strategies to improve access.
Geographic Scope: 
Client Situation
The client wanted to gather the payer and employer perspective on how the migraine landscape is evolving, and pressure test key strategic options as well as messages that they had developed. The employers included: Coca-Cola Company, Metro Nashville Public Schools, St. Louis Community College, and Vibra Healthcare.
Trinity’s Solution
Trinity conducted an unblinded advisory board with a diverse set of payers and employee benefit managers to understand current perceptions of the migraine landscape and the employer interaction with payers as it pertains to influencing employee access to novel migraine therapies.
Deliverables
- Moderator Guide targeting each advisory board stakeholder
- Pre-Survey and Workbook materials designed to capture individual data responses
- Two advisory board sessions where the client played an active role – including individual payer and employer breakout sessions
- Final Report and Executive Summary synthesizing live / written payer and employer insights, highlighting strategic opportunities, challenges, and recommendations
Project Outcomes & Impact
Bringing together both payers and employers into an ad board setting created a real-world dynamic that is not often simulated through market research activities. The feedback within the section on “Cross-Stakeholder Approaches to Engagement on Migraine” provided the client with clear insights on how to effectively engage both stakeholder groups, with a primary output being a tool that payers can use to educate their employer clients on costs associated with migraine and to inform them on how to mitigate costs for their organizations.
Related Intelligence
Blog
Rise with the waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future
Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to innovate its healthcare system. The 2024 PLFSS emphasizes: The direct access scheme is expected […]
Read More
Webinars
2023 NRDL Update: An Ongoing Voyage of Innovation and Accessibility
May 1, 2024 | 12:00 – 12:45 PM ET / 18:00 – 18:45 CET
An additional session will be offered on May 7th at 16:00-16:45 (UTC+8:00) – Asia/Shanghai How can manufacturers strategize for pricing and market access success amidst the evolving landscape of China’s NRDL? As China continues to be a key pharmaceutical market, understanding the latest National Reimbursement Drug List (NRDL) trends and policy evolvement is crucial for […]
Sign Up Now
Blog
Rise with the waves: Canada – A Coming (R)evolution: Transforming Pharmaceutical Market Access
Executive Summary Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into the new Canadian Drug Agency (CDA) over the course of the next five years, […]
Read More